Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TB Alliance-Lupin Deal To Improve Pretomanid Access But India Unlikely To Benefit For Now

Viatris Has Capacity To Meet Demand

Executive Summary

While Viatris says it has sufficient capacity to meet current and future demand for tuberculosis drug pretomanid, TB Alliance has signed a non-exclusive license with Lupin. This is the second tie-up with an Indian manufacturer but the local restricted use approval means countries other than India are likely to benefit for now.

You may also be interested in...



Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy

Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.

TB Alliance CEO On Less Toxic Treatment Regimens, Pretomanid Plans

TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.

TB Vaccine Development: COVID-19 Pathways, mRNA Tech Hold Hope

With fast-tracked development and deployment of COVID-19 vaccines yielding results, experts call for similar urgency and funding impetus to progress new vaccines for TB, which still claims 4,000 lives daily. Over 15 candidates have been in development for years, with hope now abounding around the potential of new platforms like mRNA to accelerate efforts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel